Floatz logo

Prevenar 13

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Karolinska University HospitalvaccinePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

203 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Prednisone
AstraZeneca
Phase 3BBB

View all 50 →

Same molecule, other indications

Prevenar 13 is also rated in:

pneumococcal infectionActive
BBB
Indicative · Phase 4
72 / 100
View asset →
non-Hodgkin lymphomaActive
B
Indicative · Phase 4
59 / 100
View asset →
sickle cell diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →